Casey Woodring
Stock Analyst at JP Morgan
(0.96)
# 3,880
Out of 5,058 analysts
48
Total ratings
38.46%
Success rate
-10.64%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QDEL QuidelOrtho | Maintains: Underweight | $26 → $22 | $21.28 | +3.38% | 5 | Nov 7, 2025 | |
| NTRA Natera | Maintains: Overweight | $210 → $240 | $213.65 | +12.33% | 1 | Nov 7, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $15 | $15.56 | -3.60% | 1 | Nov 7, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $160 → $165 | $162.53 | +1.52% | 9 | Nov 6, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $14 → $16 | $15.23 | +5.06% | 3 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $100 → $105 | $121.97 | -13.91% | 1 | Oct 31, 2025 | |
| AVTR Avantor | Downgrades: Neutral | $14 → $12 | $11.14 | +7.72% | 1 | Oct 30, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $177 → $255 | $217.28 | +17.36% | 1 | Oct 29, 2025 | |
| HOLX Hologic | Downgrades: Neutral | $78 | $74.11 | +5.25% | 6 | Oct 22, 2025 | |
| WAT Waters | Maintains: Neutral | $300 → $325 | $376.63 | -13.71% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $576.03 | +12.84% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,200 → $1,285 | $1,396.45 | -7.98% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $165 | $143.84 | +14.71% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $70 | $95.57 | -26.76% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $265 → $150 | $161.02 | -6.84% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $56 | $44.35 | +25.41% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $2.12 | +183.02% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $16.75 | +37.31% | 2 | Oct 31, 2023 |
QuidelOrtho
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $21.28
Upside: +3.38%
Natera
Nov 7, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $213.65
Upside: +12.33%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $15.56
Upside: -3.60%
Charles River Laboratories International
Nov 6, 2025
Maintains: Neutral
Price Target: $160 → $165
Current: $162.53
Upside: +1.52%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $15.23
Upside: +5.06%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $100 → $105
Current: $121.97
Upside: -13.91%
Avantor
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $11.14
Upside: +7.72%
IQVIA Holdings
Oct 29, 2025
Maintains: Overweight
Price Target: $177 → $255
Current: $217.28
Upside: +17.36%
Hologic
Oct 22, 2025
Downgrades: Neutral
Price Target: $78
Current: $74.11
Upside: +5.25%
Waters
Oct 9, 2025
Maintains: Neutral
Price Target: $300 → $325
Current: $376.63
Upside: -13.71%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $576.03
Upside: +12.84%
Oct 9, 2025
Maintains: Neutral
Price Target: $1,200 → $1,285
Current: $1,396.45
Upside: -7.98%
Oct 9, 2025
Maintains: Overweight
Price Target: $155 → $165
Current: $143.84
Upside: +14.71%
Sep 25, 2025
Maintains: Overweight
Price Target: $60 → $70
Current: $95.57
Upside: -26.76%
Apr 29, 2025
Downgrades: Neutral
Price Target: $265 → $150
Current: $161.02
Upside: -6.84%
Jun 18, 2024
Maintains: Overweight
Price Target: $54 → $56
Current: $44.35
Upside: +25.41%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $2.12
Upside: +183.02%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $16.75
Upside: +37.31%